Kindstar Globalgene Technology Inc
09960
Company Profile
Business description
Kindstar Globalgene Technology Inc is principally engaged in the provision of clinical testing services in China. It organizes the business into the following segments; hematology testing, genetic disease and rare disease testing, infectious disease testing, oncology testing, neurology testing, maternity-related testing, COVID-19-related testing, routine testing, scientific research services and CRO, and other segments provide testing services for R&D projects and others and miscellaneous services.
Contact
Biolake D2-1, 666 Gaoxin Road
East Lake High Tech Zone
Hubei Province
Wuhan
CHNSector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
3,162
Stocks News & Analysis
stocks
Eli Lilly receives FDA approval to add another oral GLP-1 to market
Wide moat Eli Lilly receives FDA approval for obesity pill.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Which of the 3 giant AI IPOs should you buy?
OpenAI, Anthropic, and Databricks are expected to go public this year at massive valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,864.80 | 34.90 | -0.39% |
| CAC 40 | 7,981.27 | 164.33 | 2.10% |
| DAX 40 | 23,298.89 | 618.85 | 2.73% |
| Dow JONES (US) | 46,565.74 | 224.23 | 0.48% |
| FTSE 100 | 10,364.79 | 188.34 | 1.85% |
| HKSE | 25,254.49 | 39.54 | -0.16% |
| NASDAQ | 21,840.95 | 250.32 | 1.16% |
| Nikkei 225 | 53,395.13 | 344.55 | -0.64% |
| NZX 50 Index | 12,912.10 | 86.23 | 0.67% |
| S&P 500 | 6,575.32 | 46.80 | 0.72% |
| S&P/ASX 200 | 8,661.80 | 23.20 | -0.27% |
| SSE Composite Index | 3,948.55 | 0.00 | 0.00% |